Accord Synergy Calls EGM on June 3, 2026 to Approve Preferential Issue of 4,00,000 Shares to Dr. Faruk Patel

The Board of Directors of Accord Synergy Limited, at its meeting held on May 6, 2026, approved two significant corporate actions: the noting of a Share Purchase Agreement (SPA) involving a change in promoter shareholding, and the approval of a preferential issue of equity shares to Dr. Faruk Patel. Following these approvals, the company has issued a Notice of Extra Ordinary General Meeting (EGM) scheduled for Wednesday, June 3, 2026, at 12:30 p.m. via Video Conferencing/Other Audio Visual Means, seeking shareholder approval for the preferential issue.

Share Purchase Agreement: Up to 40% Stake to Change Hands

The board noted and took on record the execution of an SPA dated May 6, 2026, between the existing promoters — Mr. Betulla Khan and Mrs. Roli B Khan (collectively, the "Sellers") — and Dr. Faruk Patel ("Acquirer") along with Mr. Muinulhaque Kadva ("Person Acting in Concert" or "PAC"). Accord Synergy Limited is not a party to the SPA. The key terms of the agreement are summarised below:

Parameter: Details Date of SPA: May 6, 2026 Sellers: Mr. Betulla Khan and Mrs. Roli B Khan (existing promoters) Acquirer: Dr. Faruk Patel Person Acting in Concert (PAC): Mr. Muinulhaque Kadva Shares to be Acquired: Up to 40% (up to 13,88,800 equity shares) of paid-up equity share capital Aggregate Consideration: Up to ₹5,58,74,896 Related Party Transaction: No Restrictions/Liabilities on Company: None

Pursuant to the SPA, the Acquirer will be required to make an open offer in accordance with the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations. Upon completion of the transaction and the open offer, Dr. Faruk Patel together with the PAC will acquire joint control over the company along with the existing Promoter Group and will be classified as promoters/Promoter Group of the company. The board shall also be reconstituted to include directors nominated by the Acquirer upon completion of the transaction.

Preferential Issue of Equity Shares: Key Terms

The board approved the issuance of 4,00,000 (Four Lakh) equity shares on a preferential basis to Dr. Faruk Patel, subject to shareholder approval at the EGM and other necessary regulatory clearances. The issue is in accordance with Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The details of the proposed preferential issue are as follows:

Parameter: Details Type of Securities: Equity Shares Number of Shares: 4,00,000 (Four Lakh) Face Value: ₹10/- per share Issue Price: ₹42.35/- per share Premium per Share: ₹32.35/- per share Total Aggregate Amount: ₹1,69,40,000/- Investor: Dr. Faruk Patel Relevant Date: Monday, May 4, 2026 Proposed Allottee Classification: Promoter & Promoter Group (post open offer)

The relevant date for determining the floor price is Monday, May 4, 2026, being the date 30 days prior to the EGM scheduled on June 3, 2026. The Committee of Independent Directors (IDC), at its meeting held on May 6, 2026, considered the issue price of ₹42.35/- per equity share as fair and reasonable in accordance with the SEBI ICDR Regulations, taking into account the Valuation Report from independent registered valuer Mr. Mukesh Kumar Jain (Registration No.: IBBI/RV/03/2019/12285). The voting pattern of the IDC meeting is set out below:

Sr. No.: Name of Independent Director: Vote 1. Rajnikant Prabhudas Mandavia Assent 2. Nishesh Kumar Sinha Assent

Dr. Faruk Patel is currently classified as a non-promoter. Pursuant to the completion of the open offer and the preferential issue, he shall be reclassified as a Promoter of the Company, resulting in a change in control.

Utilisation of Proceeds

The total proceeds of ₹1,69,40,000/- raised via the preferential issue are proposed to be utilised as follows:

Object of Issue: Amount to be Utilised Working capital requirements (telecom infrastructure solutions including network deployment, fiberization, turnkey project execution, and O&M services): Rs. 1,52,46,000 General corporate purposes: Rs. 16,94,000

As the issue size is less than ₹100 Crore, the company is not required to appoint a Credit Rating Agency as a Monitoring Agency to oversee the use of proceeds, in accordance with Regulation 162A of the SEBI ICDR Regulations.

Post-Issue Shareholding Impact

The preferential issue, when combined with the shares to be acquired under the SPA, will have a material impact on the shareholding structure of the company. The shareholding pattern before and after the proposed preferential issue is as follows:

Category: Pre-Issue Shares Pre-Issue % Post-Issue Shares Post-Issue % Promoter Holding (Individual – Indian): 24,99,500 71.99 28,99,500 74.88 Resident Individuals (up to ₹2 lakhs): 5,54,500 15.97 5,54,500 14.32 Resident Individuals (above ₹2 lakhs): 3,38,000 9.74 3,38,000 8.73 Non-Resident Indians (NRIs): 6,000 0.17 6,000 0.15 Bodies Corporate: 6,000 0.17 6,000 0.15 Any Other: 68,000 1.96 68,000 1.77 Grand Total: 34,72,000 100 38,72,000 100

Post the preferential issue, Dr. Faruk Patel's shareholding will stand at 10.33% (4,00,000 shares). Shares acquired through the open offer shall be over and above this number. Upon completion of the open offer and preferential issue, Dr. Faruk Patel shall be reclassified as a Promoter of the Company, resulting in a change in control.

Lock-In Period

The equity shares proposed to be allotted on a preferential basis shall be subject to lock-in in accordance with Chapter V of the SEBI ICDR Regulations. The key lock-in provisions are as follows:

Lock-In Category: Lock-In Period Entire pre-preferential shareholding of Proposed Allottee: 90 trading days from the date of trading approval Equity Shares issued to Proposed Allottee (general): 6 months from the date of trading approval Equity Shares allotted to Dr. Faruk Patel: 18 months from the date of trading approval

EGM and E-Voting Schedule

The remote e-voting period for the EGM resolution begins on May 31, 2026 at 9:00 A.M. and ends on June 2, 2026 at 5:00 P.M. The record date (cut-off date) for determining eligible voters is May 27, 2026. Members whose names appear in the Register of Members/Beneficial Owners as on the cut-off date may cast their votes electronically through the NSDL e-Voting platform. The EGM Notice has been uploaded on the company's website at www.accordsynergy.com and is also accessible on the websites of the stock exchanges and NSDL. The preferential allotment of equity shares to the proposed allottee is proposed to be completed within 15 days from the date of passing of the special resolution, subject to receipt of all regulatory approvals.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.